The MIMOSA platform is an FDA-cleared class II medical device. MIMOSA is designed for the early detection and preventative care of reperfusion injuries. Reperfusion injuries can appear in the case of peripheral vascular diseases, wounds, surgery and when the need for intensive care arises. There are no technologies that can truly assess these injuries.
Current technologies are large, expensive, and not accessible to all patients. Therefore, specialized expertise is still required to physically examine patients. A delay in the diagnosis of reperfusion injuries results in wounds, amputations, and even death. The MIMOSA platform is a class II medical device. When paired with a smartphone, it relays the images to a web portal for remote viewing. MIMOSA brings technology to the patient, allowing him to take non-invasive images from which physiological insights can be extracted. These images are taken below the surface of the skin using novel biomarkers that are predictive of outcome. Thanks to machine learning, the device can function regardless of skin pigmentation and its portability makes expert care accessible across geographic borders.
Over the last 6 months, MIMOSA was able to grow from 6 to 18 employees. It has also launched its early commercialization phase in the US. The size of the portable medical devices market is estimated to $85 Billion USD and MIMOSA’s model shows that the company can capture $200 Million in recurring annual revenue by 2025.